Research Article
Utilization and Dose Optimization of Angiotensin-Converting Enzyme Inhibitors among Heart Failure Patients in Southwest Ethiopia
Table 2
Clinical and medication related characteristics of HF patients (n=308).
| Characteristics | n (%) |
| Previous hospitalization | |
| no | 132 (42.9) |
| Yes | 176 (57.1) |
| Duration | |
| <2 | 108 (35.1) |
| >=2 | 200 (64.9) |
| NYHA class | |
| I | 22 (7.1) |
| II | 137 (44.5) |
| III | 149 (48.4) |
| Frequently identified comorbidities | |
| Ischemic heart disease | 139 (45.1) |
| Hypertension | 83 (26.9) |
| Valvular heart diseases | 66 (21.4) |
| Atrial fibrillation | 64 (20.8) |
| Diabetes mellitus | 52 (16.9) |
| Hyperthyroidism. | 22 (7.1) |
| Chronic kidney disease | 17 (5.5) |
| Number of comorbidities | |
| <2 | 115 (37.3) |
| ≥2 | 193 (62.7) |
| Number of medications | 157 (51) |
| <5 | 174 (56.5) |
| ≥5 | 144 (43.5) |
| Commonly used medications | |
| Loop diuretics | 240 (78.9) |
| ACEIs | 230 (74.7) |
| Beta-blockers | 189 (61.4) |
| ACEIs + Beta-blockers | 180 (58.4) |
| Antiplatelets | 187 (60.7) |
| Statins | 134 (43.5) |
| Potassium sparing diuretics | 68 (22.1) |
| Cardiac glycosides | 58 (18.8) |
|
|
ACEIs, angiotensin converting enzyme inhibitors; NYHA, New York Heart Association.
|